Amicus Therapeutics (FOLD) is presenting updated results Wednesday from a small clinical trial involving patients with the rare and debilitating Pompe disease. Amicus’ drug continues to improve walking performance and stabilize lung function in patients followed for up to one year.

Data from this same Pompe disease study were last presented by Amicus in October.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.